Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · ZYDUS LIFESCIENCES LTD · 29 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
ZYDUS LIFESCIENCES LTD
NSE: ZYDUSLIFE · BSE: 532321
NSE: ZYDUSLIFE · BSE: 532321
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
ZYDUS LIFESCIENCES LTD
StateQ1 FY27 filed
Last close · 28 Oct 2026₹1,175.50
Market cap₹117.3k cr
TTM P/E · P/B · EV/EBITDA26.2 · 3.97 · 15.6
ZYDUS LIFESCIENCES LTD is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 15,265 | 17,237 | 19,547 | 23,242 | 27,148 |
| EBITDA (ex other income) | 3,453 | 3,256 | 5,370 | 6,839 | 7,959 |
| margin % | 22.6 | 18.9 | 27.5 | 29.4 | 29.3 |
| Owners' profit | 4,487 | 1,960 | 113 | 147 | 5,040 |
| EPS, as reported (₹) | 43.84 | 19.30 | 38.14 | 44.97 | 50.09 |
| ROE % · ROCE % | 24.2 · 14.8 | 10.6 · 13.4 | 18.0 · 20.4 | 17.7 · 22.0 | 17.3 · 19.2 |
| Debt / equity (x) | 0.22 | 0.06 | 0.03 | 0.12 | 0.40 |
| Cash from operations | 2,078 | 2,689 | 3,228 | 6,777 | 2,117 |
| Capex | (1,203) | (1,031) | (907) | (1,713) | (3,394) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · ZYDUS LIFESCIENCES LTD · 29 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5,237 | 5,269 | 6,528 | 6,574 | 6,123 | 6,865 | 7,587 | 8,017 |
| Profit before tax | 1,271 | 1,184 | 1,672 | 1,921 | 1,687 | 1,353 | 1,660 | 1,307 |
| Net profit | 920 | 1,026 | 1,244 | 1,521 | 1,239 | 1,023 | 1,341 | 990 |
| EPS (₹) | 9.06 | 10.17 | 11.64 | 14.58 | 12.51 | 10.36 | 12.65 | 9.35 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Segment revenue, FY26
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Pharmaceuticals | 22,867 | 84.2 |
| Consumer products | 1,483 | 5.5 |
| Medical technologies | 328 | 1.2 |
| Consumer Products | 2,471 | 9.1 |
| Total, before eliminations | 27,148 | 100.0 |
Source: the filed segment block, four quarters summed.
Exhibit 4: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,21,677 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,53,976 | 87.0 | 15.15 | 65.5 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,54,957 | 73.1 | 8.81 | 38.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| LAURUS LABS LIMITED | 1,17,877 | 107.7 | 21.70 | 65.6 | 16.4 | 17.2 | 7.2 | 32.0 |
| ZYDUS LIFESCIENCES LTD ◆ | 1,17,315 | 26.2 | 3.97 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| DR. REDDY S LABORATORIES | 1,11,506 | 34.5 | 2.92 | 14.9 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,10,320 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,02,829 | 50.3 | 6.21 | 28.3 | 11.7 | 10.8 | — | 27.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 5: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 26.2 | 30.8 | 66 of 158 | 59% |
| P/B | 4.0 | 3.1 | 97 of 163 | 41% |
| ROCE | 18.0 | 10.8 | 44 of 183 | 76% |
| ROE | 17.3 | 9.8 | 32 of 166 | 81% |
| Debt / Equity | 0.4 | 0.2 | 124 of 166 | 26% |
| EBITDA margin | 25.2 | 17.5 | 53 of 165 | 68% |
| Revenue growth | 22.0 | 16.3 | 65 of 161 | 60% |
| Profit growth | (34.9) | 30.9 | 124 of 158 | 22% |
| Market cap | 117315 | 806 | 5 of 181 | 98% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · ZYDUS LIFESCIENCES LTD · 29 October 2026Page 3 of 3
Exhibit 6: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 24 Oct 2026 · Zydus Lifesciences sets Q2 FY27 results and earnings call for November 4 | board shareholder meetings | low | — | — |
| 21 Oct 2026 · Zydus subsidiary Zylidac Bio partners with Prolific Machines for biologics manufacturing | compliance | low | — | — |
| 21 Oct 2026 · US FDA approves Zydus menopause patch with 180-day exclusivity | compliance | low | — | — |
| 19 Oct 2026 · Zydus Lifesciences board meeting on Nov 4 to consider Q2 results | results | low | — | — |
| 16 Oct 2026 · Zydus Lifesciences gets 'Leader' ESG rating of 71 from NSRAL for FY26 | business updates | medium | — | — |
| 15 Oct 2026 · Zydus JV to set up USD 20 million pharma plant in Sri Lanka | capex operations | high | — | — |
| 13 Oct 2026 · USFDA inspection at Zydus Moraiya plant ends with 5 observations | compliance | low | — | — |
| 13 Oct 2026 · Zydus-Formycon FYB206 Keytruda biosimilar accepted for USFDA review | business updates | high | — | — |
| 12 Oct 2026 · Zydus Therapeutics presents Phase 3 saroglitazar data for PBC at ACG 2026 | compliance | low | — | — |
| 6 Oct 2026 · Quarterly Compliance Certificate for Share Dematerialization | compliance | minimal | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in